WASHINGTON, October 30, 2026 – Imagine, for example, a radiologist sitting in a darkened suite at 6:00 a.m., tapping a stylus on a tablet as a generative AI assistant quickly produces a complicated diagnosis in real time. The speed is remarkable, yet so is the inherent danger: every time an advanced model presents a rare disease, a healthcare professional is left to wonder about the precise information that informed its training.
That quiet tension between rapid innovation and patient safety sits at the very heart of medical technology today.
As generative algorithms move from administrative applications to clinical decision-making, the regulatory bodies and industry experts are setting clear limits. It is no longer simply about avoiding the dissemination of false information. It’s all about earning the trust of the institution within the whole healthcare ecosystem.
What is important to remember is that the Food and Drug Administration in the U.S. regulates not artificial intelligence in general but rather the medical devices equipped with artificial intelligence. The FDA utilizes a risk-based approach and takes into account the use and technical attributes of the product. Additionally, the FDA employs the Total Product Life Cycle approach, which focuses on the safety of the product throughout the entire life cycle from development to monitoring and modification. The Change Control Plans help the developers describe in advance how the changes are going to be controlled.
The scale of this technological shift is already visible: as of September 2026, the FDA had authorized more than 1,600 AI-enabled medical devices in the United States.
Alongside government regulation, industry leaders have also set voluntary standards. On October 27, 2026, the medical technology trade organization AdvaMed published its official response to the FDA’s paper on generative AI, which called for risk-based oversight. The next day, on October 28, AdvaMed’s Digital Health Tech Board adopted new best practices for implementing advanced data systems in hospitals.
The formal name of the standards is “Data Access Principles & Best Practices for Introducing Technology into a Health System.” The standards set out clear expectations regarding transparency, de-identification, and data stewardship. Rather than allowing data access issues to impede the implementation of the software, the voluntary standards provide clear guidelines for data collection and sharing.
And this matters because software models are only as reliable as the datasets feeding them.
Here’s where the real-world friction lies. While the health system aims for total interoperability with electronic health records, software engineers need robust anonymized clinical records to prevent algorithm biases. In cases where patients’ medical records are concerned, vague promises will not do.
The leadership of AdvaMed, including the Chair of its Digital Health Tech Board, Robert Cohen, and its CEO, Scott Whitaker, stressed that having a set of principles helps minimize contracting delays, while patient care and privacy remain top priorities.
Some clinical observers warn that voluntary guidelines may be toothless and may lead to uneven implementation in regional hospital systems. Another group of critics believes that strict compliance guidelines pose risks of suffocating small startups unable to support big compliance departments.
One can’t expect that voluntary guidelines would solve all ethical concerns overnight. However, together with FDA oversight, proper data stewardship, and post-market evaluation, such guidelines could become a good starting point when AI should help doctors, but not replace them.
